The Use of Propranolol to Block Memory Reconsolidation in PTSD
The Use of Propranolol to Block Memory Reconsolidation in Post Traumatic Stress Disorders (PTSD)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- John D Dingell VA Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants will meet the clinical criteria of PTSD (DSM IVTR) secondary to combat exposure.
Exclusion Criteria:
- Current illicit substance use or alcohol consumption, as determined by urine toxicology and alcohol breath test.
- Any diagnosis of current comorbid psychotic disorders, bipolar disorder, or illicit substance or alcohol abuse or dependence.
- Any current prescription medication usage or supplement (dietary or herbal) usage that is contraindicated with propranolol.
- Active enrollment into any psychiatric or psychological treatment.
Any condition that contraindicates the use of propranolol, such as:
- history of bronchial asthma.
- heart block.
- sinus bradycardia.
- congestive heart failure.
- insulin-dependent diabetes.
- initial systolic blood pressure < 100 mmHg.
- Hyperthyroidism.
- Thyroid disease.
- Renal or liver impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1
Propranolol following traumatic memory
|
40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
|
|
Active Comparator: 2
Propranolol following neutral memory
|
40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
|
|
Placebo Comparator: 3
Placebo following traumatic memory
|
40mg placebo, followed 2 hrs after with 60mg placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Facial corrugator EMG
Time Frame: Change in Facial corrugator EMG from baseline at 1 month post-intervention
|
Change in Facial corrugator EMG from baseline at 1 month post-intervention
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
CAPS score
Time Frame: Change in CAPS score from baseline at 1 month post-intervention
|
Change in CAPS score from baseline at 1 month post-intervention
|
|
PCL-M score
Time Frame: Change in PCL-M score from baseline at 1 month post-intervention
|
Change in PCL-M score from baseline at 1 month post-intervention
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Deane Aikins, PhD, Wayne State University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Trauma and Stressor Related Disorders
- Stress Disorders, Traumatic
- Stress Disorders, Post-Traumatic
- Physiological Effects of Drugs
- Adrenergic beta-Antagonists
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Anti-Arrhythmia Agents
- Antihypertensive Agents
- Vasodilator Agents
- Propranolol
Other Study ID Numbers
Other Study ID Numbers
- HIC 0703002443
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.